Our Approach

Our lead asset, STX-101, is a novel 

5-HT3 Receptor Partial Agonist offering a clinically validated mechanism that ensures a safer therapeutic profile and avoids the Black Box safety limitations of full 5-HT3R antagonists. 

Low Anterior Resection Syndrome (LARS) is rare, debilitating life-long post-surgical functional gastrointestinal disorder in rectal cancer survivors with no approved therapy, representing a $2B+ U.S. market opportunity. Two positive randomized trials demonstrate the efficacy of full 5-HT3R antagonists in LARS.